Lakefront Biotherapeutics (GLPGF) Gross Margin (2021 - 2026)
Lakefront Biotherapeutics' (GLPGF) quarterly Gross Margin came in at 24.9% in Q2 2026, down 6795.0% year-over-year from 0.37% in Q2 2025, and down 4.04% quarter-over-quarter from 25.95% in Q1 2026.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Gross Margin (2021 - 2026) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Gross Margin for 6 consecutive years, with 24.9% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Gross Margin fell 6795.0% year-over-year to 24.9% in Q2 2026; TTM through Jun 2026 was 2900.54%, a 298969.0% decrease from a year earlier, with the FY2025 full-year figure at 2573.5%, down 266086.0% from the prior year.
- Gross Margin was 24.9% for Q2 2026 at Lakefront Biotherapeutics, down from 25.95% in the prior quarter.
- Over five years, Gross Margin peaked at 102.45% in Q4 2022 and troughed at 3197.73% in Q4 2025.
- A 5-year average of 96.56% and a median of 93.43% in 2023 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin soared 491 bps in 2024 and tumbled 329320 bps in 2025, its largest moves.
- Over 5 years, Gross Margin stood at 102.45% in 2022, then slipped by 6 bps to 96.69% in 2023, then slipped by 1 bps to 95.47% in 2024, then sank by 3450 bps to 3197.73% in 2025, then surged by 101 bps to 24.9% in 2026.
- The last three Gross Margin figures came in at 24.9% (Q2 2026), 25.95% (Q1 2026), and 3197.73% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | 80.31% |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | 24.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.90% |
| Mar 31, 2026 | 25.95% |
| Dec 31, 2025 | -3,197.73% |
| Sep 30, 2025 | 84.70% |
| Jun 30, 2025 | 92.85% |
| Mar 31, 2025 | 81.69% |
| Dec 31, 2024 | 95.47% |
| Sep 30, 2024 | 89.49% |
| Jun 30, 2024 | 97.87% |
| Mar 31, 2024 | 95.92% |
| Dec 31, 2023 | 96.69% |
| Sep 30, 2023 | 90.62% |
| Jun 30, 2023 | 92.96% |
| Mar 31, 2023 | 93.90% |
| Dec 31, 2022 | 102.45% |
| Sep 30, 2022 | 98.21% |
| Jun 30, 2022 | 98.12% |
| Mar 31, 2022 | 97.86% |
| Dec 31, 2021 | 101.11% |
| Sep 30, 2021 | 99.78% |